A new journal in town…
If, like me, you miss the late Acumen Journal, you’ll be glad to hear that a very similar journal has […]
If, like me, you miss the late Acumen Journal, you’ll be glad to hear that a very similar journal has […]
I’ll be giving a talk on career development in biotechnology at UNC-Chapel Hill on Wednesday May 16th at 4pm in
What does Greenpeace oppose more: Patents, or genetic modification? This question has been answered in a recent patent case where
My article on the top five biotechnology blogs is up at Biotech360. Hope I don’t get too much hatemail over
India’s biotechnology industry has the potential to become a major driver of the country’s economy, but is challenged by one
Indian biotechnology: Full of promise, challenged by patents Read Post »
I’ve been asked quite a bit recently to talk about my career path. I usually begin my talks by explaining
I previously posted how price controls and compulsory licensing give buyers more power … for a price and Abbott’s spat
Coming soon, a new biotechnology magazine from The Scientist called Biotech 360. I’ve been asked to compile a list of
In response to Thailand’s decision to issue compulsory licenses for Kaletra and for Plavix, effectively bypassing their patents by purchasing
Welcome to the April 10, 2007 edition of Carnival of Biotechnology. Finance and business development On Pharma presents a report
Get new actionable insights and updates from BiotechBlog